Research Title: Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Sponsor: The EMMES Corporation
Principal Investigator: Robert A Stoltz, M.D., Ph.D.
Description: SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for 12 months. SCORE2 is designed as a non-inferiority trila, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.
Start Date: September 2014
Project Personnel: Leslie Marcus, CCRC; Halie Sklanka, CRC
Location(s): Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060